Centiva Capital’s ImmunityBio IBRX Stock Holding History

Centiva Capital’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-51,692	Closed	-$94.1K	–	1790
2023 Q1	$94.1K	Buy	+51,692	New	+$161K	﹤0.01%	1349
2022 Q3	–	Sell	-21,076	Closed	-$78K	–	1649
2022 Q2	$78K	Buy	+21,076	New	+$84.7K	﹤0.01%	1452

Other funds holding IBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

National Bank of Canada Montreal, Quebec, Canada $140B AUM 46.34% 1-Year Est. Return

Allen Holding New York $1.01B AUM 14.43% 1-Year Est. Return

Centiva Capital's IBRX Position: Q2 2023 in Review

Centiva Capital sold out of ImmunityBio (IBRX) in Q2 2023, closing a stake of 51,692 shares — an estimated $94.1K sold.

Centiva Capital first reported a position in IBRX in Q2 2022 and held it in 2 quarters. The position peaked at $94.1K in Q1 2023. 117 funds tracked by Wall St. Rank hold IBRX as of Q2 2023.

Centiva Capital reported no remaining ImmunityBio position as of Q2 2023 after selling out during the quarter.
Centiva Capital sold 51,692 ImmunityBio shares in Q2 2023, an estimated $94.1K.
Centiva Capital first reported a position in ImmunityBio in Q2 2022 and held it in 2 quarters.
Centiva Capital's ImmunityBio position peaked at $94.1K in Q1 2023.
117 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2023.

Based on Centiva Capital's 13F filing for Q2 2023, filed 14 Aug 2023.